Dr Agarwals Health Care Ltd
Dr Agarwals Health Care Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Mature facilities have exhibited strong growth with a same-store sales CAGR of about 18% from FY '22 to FY '24. Mature facilities are growing at around 18% CAGR, which is expected to continue over the next 2-3 years.
From Dr Agarwals Health Care Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Mature facilities have exhibited strong growth with a same-store sales CAGR of about 18% from FY '22 to FY '24.
- For the next 2-3 years, the company expects revenue growth from mature and new facilities combined to be around 20% annually.
- Expansion is driven primarily by organic growth, with plans to open 8-10 new facilities per quarter and around 45-50 facilities per year.
- Focus on core states: Tamil Nadu, Maharashtra, Karnataka, Andhra Pradesh, Telangana; with some expansion in northern regions like Gujarat, Jammu, Punjab.
- Growth driven by increased footfall (6-7%), pricing increases (2-3%), and premiumization (6-7%).
2 more points from Dr Agarwals Health Care Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Dr Agarwals Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Focus remains predominantly on organic expansion, with plans to open 8-10 new facilities each quarter over the next few years.
- Capex for primary (eye clinic) facilities ranges between INR 30-35 lakhs, with sizes between 750-1,500 sq ft.
- Secondary facilities have a capex range of INR 4.5-7 crores, sized 4,000-7,000 sq ft (smaller in Mumbai).
- No significant equity issuance has been done so far in acquisitions; acquisitions are primarily cash-based with deferred payments over 4 years.
- Acquisitions are strategically targeted for entry into new markets (e.g., Delhi, UP, Punjab), with majority of growth in core markets via organic centers.
- Example: Under-construction flagship tertiary hospital in Chennai, expected operational by early FY 2026.
2 more points from Dr Agarwals Health Care Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dr Agarwals Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Dr Agarwals Health Care Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Dr Agarwals Health Care Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹564 Cr, net profit ₹50 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Agarwals Health Care Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Vimta Labs (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- 3B Blackbio (Q3 FY25)
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…
- Rainbow Childrens Medicare Ltd (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Dr Lal Pathlabs (Q3 FY25)
Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…
Arthneeti Pro · Annual
Dr Agarwals Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dr Agarwals Health Care Ltd Q3 FY25 results?
Mature facilities have exhibited strong growth with a same-store sales CAGR of about 18% from FY '22 to FY '24. Mature facilities are growing at around 18% CAGR, which is expected to continue over the next 2-3 years.
What is Dr Agarwals Health Care Ltd share price analysis?
Dr Agarwals Health Care Ltd currently shows a neutral. The stock trades at a P/E of 111.9 with a market cap of ₹16,519 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Agarwals Health Care Ltd planning capital expenditure?
Focus remains predominantly on organic expansion, with plans to open 8-10 new facilities each quarter over the next few years.
Keep Dr Agarwals Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.